Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

@article{Merchant2016PhaseIC,
  title={Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.},
  author={Melinda S. Merchant and Matthew E Wright and Kristin Baird and Leonard H. Wexler and Carlos Rodriguez-Galindo and Donna Bernstein and Cindy Delbrook and Maya B Lodish and Rachel J. Bishop and Jedd D Wolchok and Howard Z. Streicher and Crystal L Mackall},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 6},
  pages={1364-70}
}
PURPOSE Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol. EXPERIMENTAL DESIGN This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects ≤21 years old with recurrent or progressive solid tumors. Dose escalation cohorts received 1, 3, 5, or 10 mg/m(2) intravenously every 3 weeks in a 3 + 3 design. Response was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Fouryear survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

  • JD Wolchok, JS Weber, MaioM, B Neyns, K Harmankaya, K Chin
  • Ann Oncol 2013;24:2174–80
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…